HBR: “Turning Pharmaceuticals:
The Ethics of Drug Pricing”
1.
Which philosophy of corporate governance – shareholder capitalism or
stakeholder capitalism – do you ascribe to?
Which one do you think is more
suitable for a non-discretionary industry like pharmaceuticals?
2.
What parameters should be followed by pharmaceutical companies when
pricing their products?
3.
What is the role of government in incentivizing pharmaceutical companies to
undertake research and development for rare diseases?
4.
What risks did Turning face?
What would you recommend it do?
5.
Is there an ultimate perversion regarding for-profit organizations developing
pharmaceuticals; e.g. if a pharma company developed a simple pill to cure
cancer or diabetes would they release it??!!
BBC Podcast: “The Ethics of Pricing Lives”
You've reached the end of your free preview.
Want to read the whole page?
- Summer '15
- Management, Pharmacology
